Arcus Biosciences vs Verastem
RCUS and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RCUS and VSTM compare
Arcus Biosciences is the larger company, worth 3.0 times as much as Verastem ($2.2B against $741M).
Verastem keeps more of each dollar of sales as profit, with a net margin of −178% compared with −453% at Arcus Biosciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RCUS | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $741M |
| Share price | $17.43 | $8.18 |
| Change, 1 year | −12.8% | −3.9% |
| Change, 5 years | −63.3% | −77.0% |
| Beta (5Y) | 1.42 | 1.37 |
| Employees | 601 | 102 |
| StockData Score | ||
| Total score | 3 | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 22.2× | 7.4× (better) |
| P/B | 6.2× (better) | 73.3× |
| FCF yield | −21.0% | – |
| Fair value | $5.80 | – |
| Margin of safety | −201% | – |
| Growth | ||
| Revenue growth (TTM) | −58.3% | – |
| Revenue growth, 5Y average | 25.9% (better) | −19.0% |
| Profitability | ||
| Operating margin | −475% | −194% (better) |
| Net margin | −453% | −178% (better) |
| FCF margin | −466% | – |
| Return on equity | −114% | – |
| Financial health | ||
| Interest coverage | −43.2× (better) | −141.9× |
| Current ratio | 3.34 (better) | 1.93 |
| Altman Z-score | −1.35 (better) | −7.82 |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −12.6% | – |
| Shareholder yield | −12.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 96.3% | 109% |
| Held by insiders | 31.7% | 1.8% |
| Insider net buying, 12 months | −$9.3M | −$816K (better) |
| Short interest, % of float | 15.2% | 22.1% |
Go deeper
- RCUS stock overview
- RCUS income statement
- RCUS valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.